Abstract: A simple, economic, accurate, sensitive, specific and precise stability indicating reverse phase high performance liquid chromatographic [RP-HPLC] method for the determination of Regorafenib in pure and tablet dosage from was developed and validated. The chromatographic separation was carried out using Phenomenex Luna-C18 column (4.5x250 mm; 5 µm particle size) as a stationary phase and methanol: acetonitrile: water (55:25:20 v/v/v) as a mobile phase. The flow rate of 1 mL/min was used with PDA detection at 275 nm. The retention time of Regorafenib was 2.480 min. RP-HPLC method was developed with linearity range of 40-240 µg/mL of Regorafenib. The correlation coefficient [r 2 ] was found to be 0.9999. The assay results obtained was in good agreement with the corresponding labeled amount by developed method within range of 98.83 ± 0.6937. Accuracy of the method was confirmed by recovery studies and the recoveries were found to be between 99.61 % and 100.22 %, the corresponding %RSD was found to be 0.2029. Precision, LOD, LOQ, specificity, robustness and ruggedness were performed as per ICH Q2(R1) guidelines and were within the acceptance criteria. This method can be conveniently used to detect the possible degradation product in the dosage form of Regorafenib during stability studies (acidic, alkaline, oxidative, thermal and photolytic). The method proved to be effective on the analysis of stressed marketed tablet formulation.
Introduction
Regorafenib (REG, Figure 1 ), chemically known as 4- [4-[[[[4-chloro-3-(trifluoromethyl) phenyl] amino] carbonyl] amino]-3 -fluorophenoxy]-N -methyl-2-pyridine carboxamide hydrate with empirical formula of C21H15ClF4N4O3.H2O. Regorafenib is an oral multikinase inhibitor developed by Bayer, which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. REG shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. It is currently being studied as a potential treatment option in multiple tumor types. 1 REG demonstrated to increase the overall survival of patients with metastatic colorectal cancer. [2] [3] [4] Stivarga is being approved with boxed warning altering patients and health care professionals that severe and fatal liver toxicity occurred in patients treated with Stivarga during clinical studies. 4, 5 
Figure 1. Structure of Regorafenib
Literature review revealed that several methods were reported for the estimation of REG in tablets; it was estimated in bulk and in tablets by RP-HPLC and LC-MS. 6, 7 But to the best of our knowledge and a through literature review indicated that there is no stabilityindicating method reported for REG. The present work aims to develop a simple, precise, and accurate stability indicating RP-HPLC method for the estimation of REG in pure and in its tablet formulation through stress studies under a variety of ICH recommended test conditions and to develop a validated stability-indicating assay method. [8] [9] [10] 
Result and Discussion
In the present work, a stability indicating analytical method based on RP-HPLC using PDA detection was developed and validated for assay determination of REG in tablet dosage formulation. The analytical conditions were selected, keeping in mind the chemical nature of REG. The development trails were taken using different conditions. The column selection has been done on the basis of backpressure, peak shape, and theoretical plates and day-to-day reproducibility of the retention 
Analysis of Pharmaceutical Formulation
Tablet powder equivalent to 40 mg of REG was weighed and transferred in to 100 mL volumetric flask, 30 mL of diluent was added and sonicated for 15 min and the volume was made up to the mark with diluent. From this solution further dilution was made to get the final concentration of 160 µg/mL. A volume of 10 µL of the final solutions was injected into the system and the chromatogram was recorded. The retention time was found to be 2.491. The content of REG in the tablets [Stivarga® 40 mg, Bayer Pharma AG, India] was computed by putting value of the peak areas (Table 1) in respective standard regression equation obtained from calibration curve.
Method Validation

Linearity
Linearity was demonstrated from the standard drug solution using six concentration levels for REG. The peak areas were recorded and calibration plot was obtained by plotting peak area versus concentration of REG. The correlation coefficient results revealed that developed analytical method having excellent linearity.
Accuracy
Accuracy was calculated by addition of standard drugs to pre-analyzed sample at 3 different concentration levels and computing percentage recoveries. Standard limit of percentage recovery study is 98-102 % as per ICH guideline. From the studies it was concluded that percentage recovery study of REG complies with standard limit of ICH guideline. The results were shown in Table 2 . The percentage recoveries obtained was found to be between 99.61 and 100.22%, which indicated that the method was accurate.
Precision
Repeatability: Six repeated injections of standard and sample solutions containing 160 µg/mL of REG was prepared and the response factor of the drug peaks and %RSD were calculated. The results obtained were presented in Table 3 .
Intraday precision: Solution containing 160 µg/mL of REG was prepared from their respective standard stock solution. Analysis was replicated for 3 different times within the same day. The results of intraday precision studies were shown in Table 4 . The results revealed that the %RSD of intraday was within the permissible limits of 2%.
Interday precision: Solution containing 160 µg/mL of REG was prepared from their respective standard stock solution. Analysis was replicated for 3 different days. The results of interday precision studies were shown in Table 5 . The results revealed that the %RSD of interday were within the permissible limits of 2%. 
Limit of Detection (LOD) and Limit of Quantitation (LOQ)
The Limit of Detection (LOD) and Limit of Quantification (LOQ) of the developed method were calculated from the standard deviation of the yintercepts and slop of the calibration curve of REG. The results of LOD and LOQ for REG obtained were presented in Table 6 . 
Robustness
Variation in the flow rate, mobile phase, nanometer and temperature has been made to the analytical method in order to evaluate and measure the capacity of the method to remain unaffected by such variations. The % RSD was found to be less than 2. The results were shown in Table 7 .
Ruggedness
Ruggedness of the method was confirmed by the analysis of formulation by the different analyst. The results were shown in Table 8 . 
System suitability
System suitability was established to determine the adequate reproducibility of the proposed method. Parameters including asymmetry factor, theoretical plates, repeatability of peak area and retention time were calculated. The results were shown in Table 9 . 
Forced Degradation Study
Forced degradation studies were performed to evaluate the stability indicating properties [Specificity] of the proposed method. REG was subjected to neutral, acid, base, oxidation, thermal and photo degradation to ensure the effective separation of degradation peaks and main peak. From the degradation of these solutions under the stressed condition gave us an idea about the origin of degrading products. Degradants did not show any interference with the elution of drug peak. Hence, the method is stability indicating. The results of degradation studies were shown in Table 10 .
Conclusion
A simple, sensitive, precise and accurate stability indicating RP-HPLC analytical method was developed for the estimation of REG in pure and tablet dosage form. The method was successfully validated and proved as linear, precise, accurate and robust. Documented evidences of the present work suggested that the developed method was an economical one in terms of lower acetonitrile concentration for the estimation of the drug and can be successfully employed for routine analysis in quality control laboratories. 
Experimental
Material
Preparation of mobile phase
The diluent was prepared by mixing 55 mL of methanol, 25 mL of acetonitrile and 20 mL of water and the resulting solution was sonicated for 15 min and it was used as mobile phase.
Preparation of standard stock solution
Quantity of REG equivalent to 40 mg was weighed and transferred in to a 100 mL volumetric flask, 30 mL of mobile phase was added and sonicated for 15 min and the volume was made up to the mark with mobile phase. From this solution further dilution was made to get the final concentration of 160 µg/mL, 10 µL of the final solutions were injected into the system and the chromatograms were recorded. 
Preparation of sample stock solution
Tablet powder equivalent to 40 mg of REG was weighed and transferred in to 100 mL volumetric flask, 30 mL of mobile phase was added and sonicated for 15 min and the volume was made up to the mark with mobile phase. From this solution further dilution was made to get the final concentration of 160 µg/mL, 10 µL of the final solution were injected into the system and the chromatograms were recorded.
Forced Degradation Studies of REG
Control Sample
A quantity tablet powder equivalent to 40 mg of REG was accurately weighed and transferred to 100 mL volumetric flask and it is dissolved in 10 mL of the mobile phase. The solution was sonicated for few minutes to dissolve the drug completely. Then it is filtered through 0.45 µ filter and the volume was made up to 100 mL with mobile phase. Further pipette 4 mL of the above stock solution and transferred to 10 mL volumetric flask and made up to 10 mL with mobile phase to get the final concentration of 160 µg/mL of REG and 10 µL of the solutions were injected in to the system and the chromatograms were recorded.
Neutral Degradation Studies
A quantity tablet powder equivalent to 40 mg of REG was accurately weighed and transferred to 100 mL volumetric flask and it is dissolved in 10 mL of the mobile phase. The solution was sonicated for few minutes to dissolve the drug completely. Then it is filtered through 0.45 µ filter and the volume was made up to 100 mL with mobile phase. Further pipette 4 mL of the above stock solution and transferred to 10 mL volumetric flask and made up to 10 mL with mobile phase to get the final concentration of 160 µg/mL of REG and the solution was refluxed in water bath for 30 minutes at 80 0 C and 10 µL of the refluxed solutions were injected in to the system and the chromatograms were recorded.
Acid Degradation Studies
A quantity tablet powder equivalent to 40 mg of REG was accurately weighed and transferred to 100 mL volumetric flask and it is dissolved in 10 mL of the mobile phase. The solution was sonicated for few minutes to dissolve the drug completely. Then it is filtered through 0.45 µ filter and the volume was made up to 100 mL with mobile phase, 4 mL of the above stock solution was transferred to 10 mL volumetric flask to that 4 mL of 2 N hydrochloric acid was added and refluxed for 30 minutes at 80 0 C. The resulting solution was diluted to 10 mL with mobile phase to get the final concentration of 160 µg/mL of REG and 10 µL of the refluxed solutions were injected in to the system and the chromatograms were recorded.
Alkaline Degradation Studies
A quantity tablet powder equivalent to 40 mg of REG was accurately weighed and transferred to 100 mL volumetric flask and it is dissolved in 10 mL of the mobile phase. The solution was sonicated for few minutes to dissolve the drug completely. Then it is filtered through 0.45 µ filter and the volume was made up to 100 mL with mobile phase, 4 mL of the above stock solution was transferred to 10 mL volumetric flask to that 4 mL of 2 N sodium hydroxide was added and refluxed for 30 minutes at 80 0 C. The resulting solution was diluted to 10 mL with mobile phase to get the final concentration of 160 µg/mL of REG and 10 µL of the refluxed solutions were injected in to the system and the chromatograms were recorded.
Oxidative Degradation Studies
A quantity tablet powder equivalent to 40 mg of REG was accurately weighed and transferred to 100 mL volumetric flask and it is dissolved in 10 mL of the mobile phase. The solution was sonicated for few minutes to dissolve the drug completely. Then it is filtered through 0.45 µ filter and the volume was made up to 100 mL with mobile phase, 4 mL of the above stock solution was transferred to 10 mL volumetric flask to that 4 mL of 3 % hydrogen peroxide [H2O2] was added and refluxed for 30 minutes at 80 0 C. The resulting solution was diluted to 10 mL with mobile phase to get the final concentration of 160 µg/mL of REG and 10 µL of the refluxed solutions were injected in to the system and the chromatograms were recorded.
Thermal Degradation Studies
A quantity tablet powder equivalent to 40 mg of REG was accurately weighed and transferred to 100 mL volumetric flask and it is dissolved in 10 mL of the mobile phase. The solution was sonicated for few minutes to dissolve the drug completely. Then it is filtered through 0.45 µ filter and the volume was made up to 100 mL with mobile phase. Further pipette 4 mL of the above stock solution and transferred to 10 mL volumetric flask and made up to 10 mL with mobile phase to get the final concentration of 160 µg/mL of REG and the solution was placed in oven at 80 0 C for 48 hours, 10 µL of the solutions were injected in to the system and the chromatograms were recorded.
Photolytic Degradation Studies
A quantity tablet powder equivalent to 40 mg of REG was accurately weighed and transferred to 100 mL volumetric flask and it is dissolved in 10 mL of the mobile phase. The solution was sonicated for few minutes to dissolve the drug completely. Then it is filtered through 0.45 µ filter and the volume was made up to 100 mL with mobile phase. Further pipette 4 mL of the above stock solution and transferred to 10 mL volumetric flask and made up to 10 mL with mobile phase to get the final concentration of 160 µg/mL of REG and the solution was exposed to UV light by keeping the volumetric flask in UV chamber for 7 days, 10 µL of the solutions were injected in to the system and the chromatograms were recorded.
